Ding B, Mai B, Liu T, Liu C, Bao H, Hu J
Diagn Pathol. 2024; 19(1):135.
PMID: 39379998
PMC: 11460102.
DOI: 10.1186/s13000-024-01555-5.
Majchrzak K, Hentschel E, Honzke K, Geithe C, von Maltzahn J
Front Cell Dev Biol. 2024; 12:1378548.
PMID: 39050890
PMC: 11266305.
DOI: 10.3389/fcell.2024.1378548.
Patel R, Cooper D, Kadakia K, Allen A, Duan L, Luo L
Commun Biol. 2024; 7(1):608.
PMID: 38769385
PMC: 11106276.
DOI: 10.1038/s42003-024-06262-x.
Unat B
Cureus. 2024; 16(3):e57082.
PMID: 38681356
PMC: 11052699.
DOI: 10.7759/cureus.57082.
Kahsay A, Rodriguez-Marquez E, Lopez-Perez A, Hornblad A, von Hofsten J
Sci Rep. 2022; 12(1):17149.
PMID: 36229514
PMC: 9561152.
DOI: 10.1038/s41598-022-21525-5.
Hyperactive Akt1 Signaling Increases Tumor Progression and DNA Repair in Embryonal Rhabdomyosarcoma RD Line and Confers Susceptibility to Glycolysis and Mevalonate Pathway Inhibitors.
Codenotti S, Zizioli D, Mignani L, Rezzola S, Tabellini G, Parolini S
Cells. 2022; 11(18).
PMID: 36139434
PMC: 9497225.
DOI: 10.3390/cells11182859.
Bioelectric Dysregulation in Cancer Initiation, Promotion, and Progression.
Sheth M, Esfandiari L
Front Oncol. 2022; 12:846917.
PMID: 35359398
PMC: 8964134.
DOI: 10.3389/fonc.2022.846917.
[Genomic classification and survival of patients with rhabdomyosarcoma: a report from an international consortium].
Sparber-Sauer M
Strahlenther Onkol. 2022; 198(4):404-407.
PMID: 35230459
DOI: 10.1007/s00066-022-01908-3.
K-Ras and p53 mouse model with molecular characteristics of human rhabdomyosarcoma and translational applications.
Nakahata K, Simons B, Pozzo E, Shuck R, Kurenbekova L, Prudowsky Z
Dis Model Mech. 2022; 15(2).
PMID: 35174853
PMC: 8844455.
DOI: 10.1242/dmm.049004.
Clinicopathologic and survival correlates of embryonal rhabdomyosarcoma driven by RAS/RAF mutations.
Agaram N, Huang S, Tap W, Wexler L, Antonescu C
Genes Chromosomes Cancer. 2021; 61(3):131-137.
PMID: 34755412
PMC: 8956004.
DOI: 10.1002/gcc.23010.
Pioneer factors in development and cancer.
Sunkel B, Stanton B
iScience. 2021; 24(10):103132.
PMID: 34632331
PMC: 8487031.
DOI: 10.1016/j.isci.2021.103132.
Expression of oncogenic HRAS in human Rh28 and RMS-YM rhabdomyosarcoma cells leads to oncogene-induced senescence.
Li J, Kovach A, DeMonia M, Slemmons K, Oristian K, Chen C
Sci Rep. 2021; 11(1):16505.
PMID: 34389744
PMC: 8363632.
DOI: 10.1038/s41598-021-95355-2.
and are candidate genes for differential diagnosis between pre-chemotherapy embryonic and alveolar rhabdomyosarcoma in pediatric patients.
Sun N, Yang Y, Wang S, Zhang J, Gui J, Tai J
Pediatr Investig. 2021; 5(2):106-111.
PMID: 34179706
PMC: 8212716.
DOI: 10.1002/ped4.12278.
Genetics of congenital solid tumors.
Jurca M, Ivascu M, Jurca A, Kozma K, Magyar I, Sandor M
Rom J Morphol Embryol. 2021; 61(4):1039-1049.
PMID: 34171053
PMC: 8343493.
DOI: 10.47162/RJME.61.4.06.
Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium.
Shern J, Selfe J, Izquierdo E, Patidar R, Chou H, Song Y
J Clin Oncol. 2021; 39(26):2859-2871.
PMID: 34166060
PMC: 8425837.
DOI: 10.1200/JCO.20.03060.
FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma.
Milewski D, Shukla S, Gryder B, Pradhan A, Donovan J, Sudha P
Oncogene. 2021; 40(12):2182-2199.
PMID: 33627785
PMC: 8005492.
DOI: 10.1038/s41388-021-01694-9.
Refractory alveolar rhabdomyosarcoma in an 11-year-old male.
Ricker C, Woods A, Simonson W, Lathara M, Srinivasa G, Rudzinski E
Cold Spring Harb Mol Case Stud. 2021; 7(1).
PMID: 33436392
PMC: 7903883.
DOI: 10.1101/mcs.a005983.
Germline Cancer Predisposition Variants in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Li H, Sisoudiya S, Martin-Giacalone B, Khayat M, Dugan-Perez S, Marquez-Do D
J Natl Cancer Inst. 2020; 113(7):875-883.
PMID: 33372952
PMC: 8246828.
DOI: 10.1093/jnci/djaa204.
Defining an embryonal rhabdomyosarcoma endotype.
Ricker C, Crawford K, Matlock K, Lathara M, Seguin B, Rudzinski E
Cold Spring Harb Mol Case Stud. 2020; 6(2).
PMID: 32238403
PMC: 7133750.
DOI: 10.1101/mcs.a005066.
Cell growth potential drives ferroptosis susceptibility in rhabdomyosarcoma and myoblast cell lines.
Codenotti S, Poli M, Asperti M, Zizioli D, Marampon F, Fanzani A
J Cancer Res Clin Oncol. 2018; 144(9):1717-1730.
PMID: 29971532
DOI: 10.1007/s00432-018-2699-0.